INS and schizophrenia: A recent study grouped schizophrenia patients treated with APs by quartiles of increasing metabolic impairments (indicated by fasting insulin and BMI) and found palmitoleic acid was significantly elevated with increasing metabolic impairments (p =  < 0.0001, fdr 0.02%)42.